Diagnostics & Research — industry outlook

Period: 2026-09-15 to 2026-10-06
Events: 9
Generated: 2026-10-06T06:30:00.003Z

AI-Driven Revenue Acceleration and Platform Scaling

Companies are positioning AI as a structural demand driver rather than a theoretical benefit, with specific quantitative targets for revenue growth in the 2026–2028 timeframe. Revvity (RVTY) forecasts "high content screening" demand driven by AI's ability to process datasets, viewing AI as a catalyst for wet-lab validation and noting that new product launches in 2026 will have "fairly nominal" revenue impact, with material contribution expected in 2027. Twist Bioscience (TWST) projects triple-digit order growth for its AI segment in both 2026 and 2027, scaling from $25 million in 2025 to over $100 million by 2027, driven by pilot-to-scale conversions taking 18–24 months. QIAGEN (QGEN) plans to launch an AI risk scoring tool and fully automated workflow in H2 2027, viewing AI as a facilitator of growth that spurs reagent consumption. Natera (NTRA) is utilizing AI to drive lab efficiency and revenue cycle management, enabling volume scaling without proportional headcount increases. Castle Biosciences (CSTL) has deployed AI agents for insurance denial management to improve payment rates, while Guardant Health (GH) integrates AI into test development to reduce feature complexity from 35,000 to 15.

Reimbursement Resolution and Pricing Realization Timelines

A dominant theme across the industry is the dependency of near-term revenue on specific regulatory decisions and the timing of commercial pricing migration. Castle Biosciences (CSTL) has removed Squamous Cell Carcinoma (SCC) revenue from 2027 models, noting a projected ~1 year timeline from draft LCD posting (late 2025) to Medicare payments (late 2027), and expects 28–30% of revenue to come from Advanced AD contingent on CMS rates published in late September 2025 with an effective date of January 1, 2027. Guardant Health (GH) targets an Average Selling Price (ASP) of ~$5,000 for Garden 360 Liquid by 2028 and a cost of goods sold (COGS) reduction to $200 by late 2027, expecting 18–24 months for commercial payers to migrate to Medicare rates. Revvity (RVTY) expects latent TB headwinds to abate in 2027, with a 200 basis point impact in FY2026. Natera (NTRA) targets a $2,000 long-term ASP for Signatera, with $150–$200 of the price increase driven by Medicare coverage decisions expected in the immediate future. QIAGEN (QGEN) cites tariff refunds as a $0.02 EPS benefit contingent on U.S. Treasury timing.

Market Recovery Cycles and End-Client Spending Patterns

Management views the macroeconomic environment as transitioning from stability to growth, though with distinct lag times and segment variations. QIAGEN (QGEN) anticipates a multi-year U.S. reshoring investment cycle from 2027–2028, while Twist Bioscience (TWST) and Revvity (RVTY) note that biotech spending recovery is expected to follow funding improvements with a 2–3 quarter lag, starting in mid-2025. Revvity (RVTY) forecasts "stably soft" academic/government spending until NIH policy stabilizes, whereas QIAGEN (QGEN) sees a stronger recovery in pharma/biotech but notes China's academic/government sector remains constrained. Charles River Laboratories (CRL) expects volume growth to be driven by a shift in client priority from price to speed, though a "hockey stick" backlog recovery is not immediate. Guardant Health (GH) expects commercial payer mix dilution in the short term as coverage expands, but anticipates ASP recovery as the base widens to under-65 populations. Twist Bioscience (TWST) highlights that academic funding shrinkage is driving a preference for its cost-efficient value proposition.

Operational Efficiency, Capacity Expansion, and Margins

Companies are prioritizing margin expansion and capacity scaling to match anticipated demand growth, with specific gross margin targets and throughput goals. Twist Bioscience (TWST) aims to achieve adjusted EBITDA break-even in Q4 and Q5, targeting a 60% gross margin by expanding chip utilization and moving up the value chain from DNA ($50) to protein ($200) to data ($300–$500). Revvity (RVTY) boasts "100%+ free cash flow conversion" and plans to achieve a "mid-to-high teens" organic growth run rate for software while transitioning to consumption-based revenue models. Natera (NTRA) targets a long-term gross margin of >70%, supported by ASP growth and reduced true-ups, despite a $100 million R&D expense for Early Cancer Detection. QIAGEN (QGEN) plans to place 150 Kaya Sprint Connect systems and aims for 5–7% underlying growth in Quantiferon versus a 4–5% market growth rate. Guardant Health (GH) expects to reach $350 per test COGS by year-end, down from $400, and is expanding commercial field force to 600–700 reps. Castle Biosciences (CSTL) has scaled its Pittsburgh lab to stay 6 months to 1 year ahead of demand, capable of 60,000 tests. Charles River Laboratories (CRL) expects manufacturing exit margins of 40%, achieved via the divestiture of the cell and gene therapy CDMO business.

Geographic Divergence: China and International Expansion

Outlooks reveal a bifurcation in geographic strategies, with some firms retreating from China diagnostics while others pivot to innovative R&D. Revvity (RVTY) is actively divesting the majority of its diagnostic business in China (currently 7% of revenue) but views the life science segment as the "strongest growing region" due to a structural shift in Chinese pharma toward innovative science. QIAGEN (QGEN) faces a persistent $30 million revenue headwind from U.S. immigration testing changes, while Middle East volumes are expected to return "over time" as the war concludes, and China academic/government spending remains challenged. Natera (NTRA) is targeting a commercial launch in Japan for colorectal cancer in early 2026, with bladder cancer approval targeted for 2026. Guardant Health (GH) maintains a 94 million person covered base for Shield, relying on U.S. commercial expansion. Castle Biosciences (CSTL) focuses on U.S. coverage resolution, noting most commercial plans lack specific policies for Tissue Cipher, relying on utilization to prove medical necessity.

M&A, Divestitures, and Capital Allocation Strategies

Firms are actively deploying capital to optimize portfolios, with a focus on tuck-ins for technology and divestitures to boost margins. QIAGEN (QGEN) deployed $9 billion in the past year, including $9 billion for Clario, and completed the divestiture of the Solventum filtration business to redeploy capital. Revvity (RVTY) completed the acquisition of Human Cell Design (HCD) in late June and expects 2026 to be the "most important new product launch year" in software history. Charles River Laboratories (CRL) divested its cell and gene therapy CDMO business to exit immature science, resulting in margin expansion from the high 30s to ~40%. Natera (NTRA) completed a large-scale sales force expansion in 2025, growing from 150–200 to >300 reps, with no further large expansions planned. Twist Bioscience (TWST) is prioritizing self-funding post-break-even to reinvest profits, having set a long-term goal to double revenue by 2031. Guardant Health (GH) is integrating Reveal Ultra and Shield to create a "single-stop shop" for oncology.